Press "Enter" to skip to content

No Benefit With Upfront Rituximab and Autologous HSCT Consolidation for Aggressive Non-Hodgkin Lymphomas – Oncology Nurse Advisor

admin 0

No Benefit With Upfront Rituximab and Autologous HSCT Consolidation for Aggressive Non-Hodgkin Lymphomas  Oncology Nurse Advisor

A recent meta-analysis suggested that for patients with aggressive non-Hodgkin lymphomas (NHLs), upfront autologous hematopoietic stem cell transplantation …

“lymphoma cancer” – Google News

(Visited 5 times, 1 visits today)

Leave a Reply

Your email address will not be published. Required fields are marked *